Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma
Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma have?
Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma published?
Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma has 2017 year in the ScholarIQ index.
What is the open-access status of Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma?
Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma has bronze oa status in the ScholarIQ index.
What is the DOI of Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma?
The DOI for Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma is on the source record.
What is the OpenAlex record for Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma?
The OpenAlex for Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma is on the source record.